SCHEMBL623481

SCHEMBL623481

N#C/C(=C/c1cccc(Cl)c1)c1cccc(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
POLB P06746 1/20 0.53
PKM P14618 1/20 0.53
KMT2A Q03164 1/20 0.53
KIF20A O95235 1/20 0.52
MAPT P10636 7/20 0.50
RAB9A P51151 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
NPC1 O15118 2/20 0.49
MAPK1 P28482 1/20 0.48
HPGD P15428 3/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
TSHR P16473 1/20 0.46
NQO2 P16083 1/20 0.45
ESR1 P03372 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623482 1.00 ALDH1A1 (0.53) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL8519245 0.87 ESR1 (0.63) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL621136 0.87 ESR1 (0.54) ALDH1A1KDM4EPOLBKIF20AMAPT
SCHEMBL621137 0.87 ESR1 (0.54) ALDH1A1KDM4EPOLBKIF20AMAPT
SCHEMBL10249600 0.87 ESR1 (0.54) ALDH1A1KDM4EPOLBKIF20AMAPT
SCHEMBL13485336 0.86 KIF20A (0.58) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL8401347 0.84 KIF20A (0.51) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL8401348 0.84 KIF20A (0.51) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL364138 0.83 MAPT (0.58) ALDH1A1KDM4EPOLBPKMKMT2A
SCHEMBL364137 0.83 MAPT (0.58) ALDH1A1KDM4EPOLBPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238619-B2 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-19 US disclosed
US-8877794-B2 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2014-11-04 US disclosed
US-20140256701-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-11 US disclosed
EP-2603487-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2013-06-19 EP disclosed
US-20120077796-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT LABORATORIES (US) 2012-03-29 US disclosed
WO-2012020130-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256701-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY KCNT1, CEPT1, PIGT ALDH1A1 934/4885KDM4E 2065/4885POLB 3073/4885
US-20120077796-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY KCNT1, CEPT1, PIGT ALDH1A1 934/4885KDM4E 2065/4885POLB 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.